Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric shocks + chemo: new hope for liver tumors?

NCT ID NCT05267080

Knowledge-focused Sponsor: Cardiovascular and Interventional Radiological Society of Europe Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is a registry that collects information on how well electrochemotherapy (ECT) works for people with liver cancer. ECT uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The study will follow 250 adults with primary or secondary liver cancer who are already scheduled to receive ECT, tracking tumor control, side effects, and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with primary or secondary liver cancer referred to local ablative treatment by multidisciplinary tumour board and treated with pECT by decision of the interventional radiologist in charge.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Primary or secondary liver cancer * Referral to local ablative treatment by multidisciplinary tumour board and decision to treat with pECT by interventional radiologist in charge * Planned treatment with pECT using the CLINIPORATOR * Signed informed consent form Exclusion Criteria: Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary liver cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer secondary malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary liver cancer Secondary liver cancer

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, France

  • Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Italy

  • Helios Park-Klinikum

    Leipzig, Germany

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • Hôpital Européen Georges-Pompidou

    Paris, France

  • Institut Gustave Roussy

    Paris, France

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

  • Policlinico Universitario A. Gemelli

    Rome, Italy

  • Städtisches Klinikum Braunschweig

    Braunschweig, Germany

  • University Hospital Regensburg

    Regensburg, Germany

  • University of Szeged

    Szeged, Hungary

  • Universitätsklinikum Halle

    Halle, Germany

  • Vilnius University Hospital Santariškių Klinikos

    Vilnius, Lithuania

  • WEGE Klinik

    Bonn, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.